Edwards Lifesciences Corporation EW
At closeNov 3, 2026, 6:40 PM EST
After hours · Nov 3, 6:40 PM ET
- YTD
- +11.66%
- 1 year
- +14.59%
- Market cap
- 54.87B
- Revenue (ttm)
- 6.51B
- Profit margin
- 15.43%
- EPS (ttm)
- 1.68
- Shares out
- 575.80M
- P/E ratio
- 56.66
- Forward P/E
- 28.16
- YTD return
- +11.66%
- 1-year return
- +14.59%
- Volume
- 6.56M
- Avg volume
- 3.47M
- Open
- 93.67
- Previous close
- 93.26
- Day's range
- 93.27 – 96.09
- 52-week range
- 74.66 – 96.29
- Beta
- 0.83
- Analysts
- Buy
- Price target
- 101.87 (+7.0%)
- Earnings date
- Nov 4, 2026
2Y +28.72 (+43.21%)
Key statistics
- Enterprise value
- 50.31B
- PEG ratio
- 1.95
- Price / sales
- 8.42
- Price / book
- 5.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 13.60%
- Free cash flow
- 1.23B
- Total cash
- 4.25B
- Total debt
- 704.40M
- Return on equity
- 9.18%
- Short % of float
- 1.84%
- 50-day average
- 88.21
- 200-day average
- 85.47
Analyst view
Consensus: buy
- Target (low)
- 84.00
- Target (mean)
- 101.87
- Target (high)
- 117.00
- Strong buy5
- Buy18
- Hold7
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.73653.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 0.737 | — | — | — |
| Jul 23, 2026 | Jun 30, 2026 | 0.743 | 0.78 | +0.04 | +4.98% |
| Apr 23, 2026 | Mar 31, 2026 | 0.729 | 0.78 | +0.05 | +7.00% |
| Feb 10, 2026 | Dec 31, 2025 | 0.618 | 0.58 | -0.04 | -6.15% |
| Oct 30, 2025 | Sep 30, 2025 | 0.596 | 0.67 | +0.07 | +12.42% |
| Jul 24, 2025 | Jun 30, 2025 | 0.624 | 0.67 | +0.05 | +7.37% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2026 | Barclays | init | — | Overweight |
| Sep 11, 2026 | BTIG | reit | Buy | Buy |
| Jul 24, 2026 | Leerink Partners | up | Market Perform | Outperform |
| Jul 24, 2026 | JP Morgan | main | Overweight | Overweight |
| Jul 24, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Jul 16, 2026 | Truist Securities | main | Hold | Hold |
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- edwards.com
News
ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test 
Can Q3 Earnings Get Back On Track After Being Rattled By Big Tech's AI Prints? 
Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript 
Edwards Lifesciences Highlights PASCAL, TAVR Data Showing Patient Benefits 
Edwards Lifesciences Reports PASCAL System For Tricuspid Repair Shows Superiority Compared To Medical Therapy Alone For Six-Month Primary Endpoint Of CLASP II TR Trial 
CLASP II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System 
Edwards Lifesciences Announces Its PROGRESS Study Demonstrates Transcatheter Aortic Valve Replacement Reduced Composite Endpoint Of Death Or Heart Failure By 30%; Transcatheter Aortic Valve Replacement Lowered Heart Failure Hospitalizations By Over 50% 
Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features 
Edwards' Q3 Earnings on the Horizon: What's in the Cards? 
Curious about Edwards Lifesciences (EW) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Your note
Sign in to keep a note on EW — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOBO DONALD E JR | Officer | Sale | May 26, 2026 | 0 |
| CHOPRA DAVEEN | Officer | Sale | Aug 25, 2026 | 44,324 |
| GALLAHUE KIERAN T. | Director | Stock Award(Grant) | May 7, 2026 | 83,971 |
| LIPPIS DANIEL J | Officer | Sale | Oct 7, 2026 | 40,033 |
| LORANGER STEVEN R | Director | Stock Award(Grant) | May 7, 2026 | 84,369 |
| MISTRAS THEODORA | Chief Financial Officer | Stock Award(Grant) | Jul 8, 2026 | 99,920 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.21% | 58,789,433 | 5.60B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.53% | 37,615,952 | 3.58B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.59% | 26,411,402 | 2.51B | Jun 29, 2026 |
| State Street Corporation | 4.57% | 26,321,940 | 2.51B | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 3.96% | 22,783,175 | 2.17B | Jun 29, 2026 |
| Wellington Management Group, LLP | 2.92% | 16,827,967 | 1.60B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 18,279,615 | 1.74B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 14,919,502 | 1.42B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund | 2.17% | 12,476,018 | 1.19B | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.97% | 11,357,910 | 1.08B | Jul 30, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 7,683,257 | 731.48M | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 7,474,400 | 711.60M | Aug 30, 2026 |